Deutsche Bank initiated coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a note issued to investors on Tuesday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.
Several other equities analysts have also weighed in on ICPT. Wedbush restated an “outperform” rating and set a $253.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, August 25th. Royal Bank of Canada raised their target price on Intercept Pharmaceuticals from $200.00 to $244.00 and gave the company an “outperform” rating in a report on Tuesday, September 26th. Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. ValuEngine upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub lowered Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Intercept Pharmaceuticals has an average rating of “Hold” and a consensus target price of $144.13.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded down $0.70 during midday trading on Tuesday, reaching $60.64. The company’s stock had a trading volume of 353,697 shares, compared to its average volume of 765,504. Intercept Pharmaceuticals has a one year low of $54.98 and a one year high of $135.59. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95.
In other news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 2,566 shares of company stock worth $151,025. 4.50% of the stock is currently owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Sphera Funds Management LTD. grew its position in Intercept Pharmaceuticals by 100.0% during the second quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock worth $3,632,000 after buying an additional 15,000 shares in the last quarter. Vanguard Group Inc. grew its position in Intercept Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after buying an additional 57,149 shares in the last quarter. Dynamic Technology Lab Private Ltd grew its position in Intercept Pharmaceuticals by 85.6% during the second quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 3,136 shares in the last quarter. Asymmetry Capital Management L.P. acquired a new stake in Intercept Pharmaceuticals during the second quarter worth about $3,580,000. Finally, Senvest Management LLC acquired a new stake in Intercept Pharmaceuticals during the third quarter worth about $33,883,000. 73.80% of the stock is currently owned by institutional investors and hedge funds.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
